Sarepta touts three-year Duchenne gene therapy data after patient deathsnews2026-01-26T16:17:47+00:00January 26th, 2026|Endpoints News|
Genmab halts enrollment for cancer drug from ProfoundBio buyoutnews2026-01-26T11:31:04+00:00January 26th, 2026|Endpoints News|
EU kicks off one-year pilot to expedite multinational trialsnews2026-01-23T19:24:15+00:00January 23rd, 2026|Endpoints News|
Sanofi’s Phase 3 eczema data cloud hopes for potential immunology blockbusternews2026-01-23T15:39:18+00:00January 23rd, 2026|Endpoints News|
Corcept’s drug extends patients’ lives in key ovarian cancer studynews2026-01-22T16:08:57+00:00January 22nd, 2026|Endpoints News|
IntraBio says rare disease drug passes Phase 3, will seek FDA approvalnews2026-01-21T16:05:26+00:00January 21st, 2026|Endpoints News|
Valneva withdraws chikungunya vaccine from USnews2026-01-20T18:37:12+00:00January 20th, 2026|Endpoints News|
Corvus’ new Phase 1 atopic dermatitis data meet high expectationsnews2026-01-20T12:00:19+00:00January 20th, 2026|Endpoints News|
J&J, Isomorphic sign research deal for AI-made moleculesnews2026-01-20T12:00:09+00:00January 20th, 2026|Endpoints News|
AbbVie, Genmab say Epkinly didn’t prolong overall survival in lymphoma studynews2026-01-16T21:01:22+00:00January 16th, 2026|Endpoints News|
